Heraeus Pharmaceutical Ingredients expands cancer therapy API capacity

Technical set-up of the new production line is complete and commercial production is due in 2020

Heraeus Pharmaceutical Ingredients, a business of Heraeus Precious Metals, said it has expanded capacity for Platinum-based highly potent active pharmaceutical ingredients (Pt HPAPIs) with an additional production line built at the company’s headquarters in Hanau, Germany. Details of the expansion and investment involved have not been disclosed.

The technical set-up of the new production line is now complete and commercial production is scheduled to begin in 2020 upon completion of the validation process.

Heraeus specialises in the supply of Platinum-based HPAPIs, which are a key component used in cancer chemotherapy. The company said the production expansion at the German site responds to increasing demand from cancer patients across the globe.

"We are primed and ready to meet the growing market demands from our clients for Platinum-based HPAPIs and lifesaving treatments for cancer patients," commented Dr Marcus Hannakam, Head of Heraeus’ Pharmaceutical Ingredients.

Platinum-based HPAPIs are used in chemotherapy treatments to combat a range of cancers, including lung, colorectal, ovarian and testicular cancer.

The need for Pt HPAPIs in cancer treatment has been rocketing due to demographic changes leading to more cancer cases, emerging countries gaining access to chemotherapy and usage of Platinum-based HPAPIs in combination therapy.

Heraeus is exhibiting at CPhI Worldwide 2019 in Frankfurt from 5-7 November.

Companies